Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(84)91202-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Validation of a Rapid Screening Test for HTLV-I IgG Antibodies.
Viruses
December 2022
Universidade Federal da Bahia, Salvador 40170-110, Brazil.
Initial diagnosis of human T cell lymphotropic virus (HTLV) infections is mainly based by detecting antibodies in plasma or serum using laboratory-based methods. The aim of this study was to develop and evaluate a rapid screening test for HTLV-I antibodies. Our rapid screening test uses HTLV-I p24 antigen conjugated to gold nanoparticles and an anti-human IgG antibody immobilized to a nitrocellulose strip to detect human HTLV-I p24-specific IgG antibodies via immunochromatography.
View Article and Find Full Text PDF[Prevalence of Human T-Cell Lymphotropic Virus Type 1 and 2 among Blood Donors in Jiangsu from 2016 to 2019].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2021
Department of Hematology, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu Province, China,E-mail:
Objective: To investigate the prevalence of human T-cell lymphotropic virus (HTLV) type-I/II infection among voluntary blood donors in Jiangsu (Nanjing, Suzhou, Xuzhou).
Methods: From 2016 to 2019, 408 262 samples of voluntary blood donors from four blood stations in Jiangsu Province (Jiangsu Province Blood Center, Nanjing Red Cross Blood Center, Suzhou Central Blood Station, and Xuzhou Central Blood Station) were screened for HTLV-I/II antibody by ELISA. The positive samples were sent to National Center for Clinical Laboratories for confirmation by RT-PCR and Western blot.
Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma.
Life Sci
June 2020
Department of Biology and Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Lebanon; Center for Drug Discovery, American University of Beirut, Lebanon. Electronic address:
Aims: To reduce the dose of arsenic used against human T-cell leukemia/lymphoma and to sensitize cells to drug treatment, we combined arsenic/interferon-alpha (As/IFN-α) with thymoquinone (TQ) in HTLV-I positive (HuT-102 and C91) and HTLV-1 negative (CEM and Jurkat) cell lines.
Main Methods: Cells were treated with TQ, As/IFN-α and combinations. Trypan blue and flow cytometry were used to investigate viability and cell cycle effects.
Human T-lymphotropic virus type I and breastfeeding; systematic review and meta-analysis of the literature.
Iran J Neurol
October 2018
Marvdasht Shahid Motahhari Hospital, Department of Neurology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
The human T-cell lymphotropic virus type-I (HTLV-I) is the first identified pathogenic human retrovirus. Breastfeeding has been reported to be the predominant route of vertical transmission of HTLV-I. The objective of this systematic review was to pool and evaluate the data on the transmission of HTLV-I with different infant-feeding practices on children born to HTLV-I-positive mothers.
View Article and Find Full Text PDFPhylogenetic analysis of HTLV-1 in Iranian blood donors, HIV-1 positive patients and patients with beta thalassemia.
J Med Virol
August 2018
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Human T-cell lymphoma virus (HTLV) has been associated with various disease types. Since the discovery of the virus in 1980, seven subtypes of the virus have been identified. HTLV is widespread and endemic in some regions, such as Japan, Africa, South America, and northeast Iran.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!